Xeltis
Shaping the Future of Vascular Medicine

Xeltis is transforming implant technology with groundbreaking solutions for vascular and valve replacement, breaking the cycle of repeated surgeries and complications. Its innovative artificial vessels and valves are designed to be gradually replaced by the patient’s own healthy tissue, fostering long-term, sustainable healing.

Current vascular surgery practices still rely on materials that have remained largely unchanged for decades, offering limited innovation. Physicians must choose between animal-derived or synthetic materials, both of which are associated with high rejection rates, susceptibility to infection and frequent reinterventions due to the limited lifespan of the materials.

At the heart of Xeltis’ groundbreaking approach is its proprietary Endogenous Tissue Restoration (ETR) platform, known as RestoreX, which leverages Nobel Prize-winning advancements in polymer technology. The platform utilizes electrospun nanofibers to create implants that act as scaffolds, guiding the body to regenerate its own healthy tissue. Over time, these implants are naturally replaced by the patient’s own cells, dramatically reducing the risk of thrombosis, stenosis, calcification, and infection—the leading causes of implant failure.

Its ongoing clinical programs are redefining the standard of care, offering a new paradigm in long-term functionality and enhanced patient safety. By reducing the need for reinterventions and minimizing infection risks, these implants present a breakthrough in both treatment effectiveness and quality of life. In addition, the implants are compatible with standard surgical techniques, making their integration into clinical practice seamless. Scalable and easy to store, Xeltis implants are designed for diverse clinical environments, ensuring that healthcare providers and patients worldwide will benefit from these innovative, life-changing solutions.

Among its line of solutions is aXess, a restorative conduit that enables the creation of a new, long-term living vessel. Designed for end-stage renal disease patients, it provides vascular access for hemodialysis.

For the 3.5 million patients undergoing routine dialysis annually, aXess replaces synthetic grafts and central venous catheters, offering the durability of arteriovenous fistulas while significantly accelerating dialysis readiness. Clinical trials show its effectiveness, demonstrating zero percent infection rates, 80 percent primary patency and reduced need for reintervention.

For individuals undergoing coronary artery bypass surgery (CABG), Xeltis introduces Xabg, a restorative conduit which enables continued blood flow in coronary artery disease patients, eliminating the need for vein harvesting. Facilitating the natural development of durable, long-term living vessels, it addresses the needs of millions affected by cardiovascular diseases each year. With first-in-human trials showcasing promising outcomes, including high long-term patency rates and reduced procedural risks, Xabg is poised to transform the future of CABG.

For patients with congenital heart malformations requiring valve replacement surgery, Xeltis offers Xplore-2 pulmonary heart valve, a self-healing alternative which turns into a living valve made of the patient’s own tissue. This reduces the risks of reinterventions caused by narrowing of the valve due to calcification, stenosis or infections. Clinical data reveal excellent initial results, with no device-related complications or reoperations after 12 months. It marks a significant advancement in treating pediatric and adult patients with heart valve conditions.

With its operations spanning Europe and the United States, Xeltis collaborates with leading researchers, clinicians and investors to advance its mission. Backed by a robust clinical pipeline, its solutions have been implanted in over 90 patients, with more than 20 demonstrating positive outcomes over five years. This strong foundation highlights Xeltis’ commitment to transforming vascular medicine on a global scale.

Xeltis’ ambitions go beyond innovation. It seeks to redefine standards of care for millions of patients worldwide. As it continues to pioneer transformative solutions, it is setting the gold standard reshaping the future of vascular and valve replacement for the better.